Pallas Capital Advisors LLC Buys New Shares in Medpace Holdings, Inc. $MEDP

Pallas Capital Advisors LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,142 shares of the company’s stock, valued at approximately $1,134,000.

Several other hedge funds also recently bought and sold shares of the company. Elyxium Wealth LLC bought a new stake in Medpace during the fourth quarter valued at about $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace in the second quarter worth about $31,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Medpace in the second quarter worth about $34,000. Basecamp Wealth Advisors LLC boosted its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after acquiring an additional 45 shares during the period. Finally, Quarry LP purchased a new stake in shares of Medpace during the third quarter worth about $35,000. Institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 458 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total value of $274,978.62. Following the completion of the transaction, the chief executive officer directly owned 603,978 shares of the company’s stock, valued at approximately $362,622,351.42. This trade represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the sale, the director owned 12,275 shares in the company, valued at $7,430,916.75. This represents a 8.50% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is owned by insiders.

Medpace Stock Down 1.1%

Shares of Medpace stock opened at $590.30 on Wednesday. The firm has a market cap of $16.48 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 2.58 and a beta of 1.15. The business has a 50-day moving average price of $541.49 and a 200-day moving average price of $491.49. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MEDP. Robert W. Baird lifted their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Truist Financial upped their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and boosted their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average target price of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.